Crossmark

Psoriasis-Arthritis: Zulassungserweiterung für Risankizumab

Crossref DOI link: https://doi.org/10.1007/s15002-022-3515-4

Published Online: 2022-04-25

Published Print: 2022-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hofmann-Aßmus, Marion
License Information

Text and Data Mining valid from 2022-04-01

Version of Record valid from 2022-04-01
More Information

Article History

First Online: 25 April 2022

Free to read: This content has been made available to all.